Clinical Trials Directory

Trials / Conditions / Secondary Central Nervous System Lymphoma

Secondary Central Nervous System Lymphoma

12 registered clinical trials studyying Secondary Central Nervous System Lymphoma — 7 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
NCT07137494
Memorial Sloan Kettering Cancer CenterPhase 1
RecruitingA Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
NCT07082868
Memorial Sloan Kettering Cancer CenterPhase 1
RecruitingGlofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
NCT06922604
City of Hope Medical CenterPhase 1
RecruitingZanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) L
NCT05681195
Baptist Health South FloridaPhase 2
Active Not RecruitingA Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Re
NCT05485753
Sichuan Baili Pharmaceutical Co., Ltd.Phase 1 / Phase 2
RecruitingAcalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
NCT05256641
Jonsson Comprehensive Cancer CenterPhase 1 / Phase 2
RecruitingTafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
NCT05351593
James RubensteinPhase 1 / Phase 2
UnknownR-MTX-zanbrutinib in Secondary CNS Lymphoma
NCT05398224
Peking UniversityPhase 2
UnknownA Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Ne
NCT04457869
Shandong New Time Pharmaceutical Co., LTDPhase 2
RecruitingNeurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
NCT05011045
M.D. Anderson Cancer Center—
Active Not RecruitingTemozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphom
NCT03964090
National Cancer Institute (NCI)Phase 2
UnknownA Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL
NCT04438044
Beijing InnoCare Pharma Tech Co., Ltd.Phase 2